MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

About this update from Maxcyte, Inc.

[{"type":"image","alt":"MaxCyte, Inc","displaySize":"","headline":null,"caption":"MaxCyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/18aaaba351d9f5c2181ef7acd6cea89a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WYwJtM4XDMnm8G2fGhEvjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/18aaaba351d9f5c2181ef7acd6cea89a","width":300,"height":45}},"lazy":false},{"type":"text","content":"ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2025.","length":393,"tagName":"p"},{"type":"text","content":"Preliminary Unaudited Fourth Quarter and Full Year 2025 Results","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Core revenue in the fourth quarter is expected to be between $6.6 million and $6.7 million.","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Core revenue for the full year is expected to be between $29.5 million and $29.6 million.","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic Platform License (SPL) program-related revenue in the fourth quarter is expected to be between $0.4 million and $0.6 million.","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"SPL program-related revenue for the full year is expected to be between $3.3 million and $3.5 million.","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":417,"olType":false},{"type":"text","content":"Total cash, cash equivalents, and investments as of December 31, 2025, is expected to be approximately $155.6 million.","length":118,"tagName":"p"},{"type":"text","content":"“2025 was a challenging, but productive year at MaxCyte. We worked through a difficult macro environment, including rationalization of programs and inventory management from a few SPL customers, however, we reported preliminary core revenue that was in-line with our guidance range,” said Maher Masoud, President and CEO of MaxCyte. “We also made ...

More updates from Maxcyte, Inc.